FR2424031A1 - Preservatives for vaccines - contg. hydrolysed gelatin, sorbitol, culture medium and a buffer at pH 6-6.5 - Google Patents

Preservatives for vaccines - contg. hydrolysed gelatin, sorbitol, culture medium and a buffer at pH 6-6.5

Info

Publication number
FR2424031A1
FR2424031A1 FR7812053A FR7812053A FR2424031A1 FR 2424031 A1 FR2424031 A1 FR 2424031A1 FR 7812053 A FR7812053 A FR 7812053A FR 7812053 A FR7812053 A FR 7812053A FR 2424031 A1 FR2424031 A1 FR 2424031A1
Authority
FR
France
Prior art keywords
vaccine
contg
pts
stabiliser
partially hydrolysed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7812053A
Other languages
French (fr)
Other versions
FR2424031B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to FR7812053A priority Critical patent/FR2424031A1/en
Publication of FR2424031A1 publication Critical patent/FR2424031A1/en
Application granted granted Critical
Publication of FR2424031B1 publication Critical patent/FR2424031B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18451—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Vaccine compsns. contg. inactivated or attenuated virus and a stabiliser consisting of, by wt. 2.5 pts. partially hydrolysed gelatine, 2-55 pts. of a polyhydroxyl alcohol of 6C, 0.5-1.7 pts. of a cell culture medium, and physiologically acceptable buffer sufficient to adjust the pH to 6-6.5 are new. The vaccines may be for measles, mumps, German measles, chicken pox, polio, hepatitis herpes simlex 1, herpes simplex 2 or mixtures of these. Greater stability than conventional vaccine mixtures. is achieved. A typical vaccine comps. contains measles virus and stabiliser prepd. from 35.7g partially hydrolysed gelatin 35.7g, partially hydrolysed gelatin, 35.7 sorbitol, 11.06gMedium 199 (Morgan etcoll. Proc. Sec. Exp. Biol & Med 73:1-8, 1950), 100 ml 1M sodium phosphate buffer pH 6.0 and distilled water to 1 litre. The vaccine also contained neomycin to prevent microbial growth, and was sealed in glass ampoules. This vaccine was stable after 4 months at 2-8 degrees C, whilst a similar vaccine contg. commercial stabiliser was not.
FR7812053A 1978-04-24 1978-04-24 Preservatives for vaccines - contg. hydrolysed gelatin, sorbitol, culture medium and a buffer at pH 6-6.5 Granted FR2424031A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7812053A FR2424031A1 (en) 1978-04-24 1978-04-24 Preservatives for vaccines - contg. hydrolysed gelatin, sorbitol, culture medium and a buffer at pH 6-6.5

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7812053A FR2424031A1 (en) 1978-04-24 1978-04-24 Preservatives for vaccines - contg. hydrolysed gelatin, sorbitol, culture medium and a buffer at pH 6-6.5

Publications (2)

Publication Number Publication Date
FR2424031A1 true FR2424031A1 (en) 1979-11-23
FR2424031B1 FR2424031B1 (en) 1981-07-24

Family

ID=9207513

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7812053A Granted FR2424031A1 (en) 1978-04-24 1978-04-24 Preservatives for vaccines - contg. hydrolysed gelatin, sorbitol, culture medium and a buffer at pH 6-6.5

Country Status (1)

Country Link
FR (1) FR2424031A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028563A1 (en) * 1979-10-29 1981-05-13 Merck & Co. Inc. Stabilizer for liquid vaccines and liquid vaccine containing said stabilizer
FR2505657A1 (en) * 1981-05-13 1982-11-19 Pasteur Institut IMPROVEMENTS IN LIVE STABILIZING AGENTS FOR THE PREPARATION OF VACCINES, AND STABILIZED VACCINES CONTAINING SAID STABILIZING AGENTS
EP0295043A2 (en) * 1987-06-08 1988-12-14 The Kitasato Institute Stabilized live attenuated vaccine and its production

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2879202A (en) * 1954-11-05 1959-03-24 American Cyanamid Co Stabilization of live viral vaccines by hexahydric alcohols
FR1296510A (en) * 1958-05-09 1962-06-22 American Cyanamid Co Method of preparing an attenuated poliomyelitis virus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2879202A (en) * 1954-11-05 1959-03-24 American Cyanamid Co Stabilization of live viral vaccines by hexahydric alcohols
FR1296510A (en) * 1958-05-09 1962-06-22 American Cyanamid Co Method of preparing an attenuated poliomyelitis virus

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028563A1 (en) * 1979-10-29 1981-05-13 Merck & Co. Inc. Stabilizer for liquid vaccines and liquid vaccine containing said stabilizer
FR2505657A1 (en) * 1981-05-13 1982-11-19 Pasteur Institut IMPROVEMENTS IN LIVE STABILIZING AGENTS FOR THE PREPARATION OF VACCINES, AND STABILIZED VACCINES CONTAINING SAID STABILIZING AGENTS
EP0065905A1 (en) * 1981-05-13 1982-12-01 Institut Pasteur Stabilizing agents for live viruses for the preparation of vaccines, and stabilized vaccines containing these stabilizing agents
US4500512A (en) * 1981-05-13 1985-02-19 Institut Pasteur Stabilizing agents for live viruses for preparing vaccines, and stabilized vaccines containing said stabilizing agents
EP0295043A2 (en) * 1987-06-08 1988-12-14 The Kitasato Institute Stabilized live attenuated vaccine and its production
EP0295043A3 (en) * 1987-06-08 1989-07-26 The Kitasato Institute Stabilized live attenuated vaccine and its production
BE1001533A3 (en) * 1987-06-08 1989-11-21 Kitasato Inst Stabilized soft and live vaccine making.
US4985244A (en) * 1987-06-08 1991-01-15 The Kitasato Institute Stabilized live attenuated vaccine and its production

Also Published As

Publication number Publication date
FR2424031B1 (en) 1981-07-24

Similar Documents

Publication Publication Date Title
ES8202584A1 (en) Stabilizer for liquid vaccines and liquid vaccine containing said stabilizer.
Hotchin et al. Lymphocytic choriomeningitis infection of mice as a model for the study of latent virus infection
CA1045546A (en) Highly attenuated cytomegalovirus vaccine and production thereof
FR2424031A1 (en) Preservatives for vaccines - contg. hydrolysed gelatin, sorbitol, culture medium and a buffer at pH 6-6.5
GB1522006A (en) Feline calicivirus vaccine and a process for the production thereof
IT1102591B (en) Preservatives for vaccines - contg. hydrolysed gelatin, sorbitol, culture medium and a buffer at pH 6-6.5
NL7803891A (en) Preservatives for vaccines - contg. hydrolysed gelatin, sorbitol, culture medium and a buffer at pH 6-6.5
PT68041A (en) Process for the preparation of a stabilized vaccine.
ZA881239B (en) Canine distemper virus vaccine
DZ1550A1 (en) A cell-free vaccine against the marek disease virus.
JPS577423A (en) Frozen or freeze-dried live measles vaccine
DK149347C (en) PROCEDURE FOR PREPARING INSULIN PREPARATIONS WITH CRYSTALS WITH 2-ZN STRUCTURE
ES2053732T3 (en) ATTENUATED VIRUSES AND VACCINE OF THE SAME FOR EMPLOYMENT AGAINST BIRD INFECTIONS CAUSED BY THE VIRUS OF TURKEY RHINOTRAQUEITIS.
PT69953A (en) Process for preparing a composition comprising a lyophilized herpes virus
ES468960A1 (en) A procedure for the preparation of an improved stabilized viral vaccine (Machine-translation by Google Translate, not legally binding)
GB1015262A (en) Virus culture
Brinton et al. Actinomycin D cytotoxicity for mouse peritoneal macrophages and effect on lactate dehydrogenase-elevating virus replication
GB878704A (en) Propagation of attenuated infectious canine hepatitis virus in trypsinized tissue cultures of pig kidney and the preparation of a vaccine therefrom
CA1054053A (en) Live virus culture vaccine against carnivore distemper and method of producing same
GB1070764A (en) Improvements in or relating to a process for culturing tissue cells
GB1349362A (en) Process for preparing live virus vaccines
UA21969A1 (en) A process for preparation of inactivated cultural vaccine against aueski disease
GB1480690A (en) Tissue culture media
PAYNE STUDIES ON ACUTE AND LATENT HERPES SIMPLEX VIRUS TYPE 1 INFECTIONS AND THE INFLUENCE OF SERUM IMMUNOGLOBULINS.
GB1161414A (en) Vaccines against Measles and process for their manufacture